[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100594182":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":31,"centralContacts":36,"locations":42,"responsibleParty":55,"collaborators":26,"id":57,"slug":58,"hasResults":59,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":26,"eligibilityCriteria":63,"healthyVolunteers":59,"sex":64,"minAge":65,"maxAge":66,"enrollmentInfo":67,"targetDuration":26,"studyType":70,"phases":71,"briefSummary":73,"conditions":74,"keywords":76,"overallStatus":79,"whyStopped":26,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":89},{"fullName":5,"class":6},"Universitas Padjadjaran","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Group A: 0.005% latanoprost gel and 308 nm excimer phototherapy","EXPERIMENTAL","* Apply 0.005% latanoprost gel to the predetermined skin lesions twice daily (morning and evening) every day for 12 weeks.\n* Phototherapy is administered at a dose based on the lesion's location and the response to previous phototherapy sessions. Phototherapy is performed twice a week for 12 weeks.",[13],"Drug: 0.005% latanoprost gel",{"label":15,"type":16,"description":17,"interventionNames":18},"Group B : 0.1% mometasone furoate cream and 308 nm excimer phototherapy","ACTIVE_COMPARATOR","* Apply 0.1% mometasone furoate cream to the predetermined skin lesions twice daily (morning and evening) for 12 weeks.\n* Phototherapy is administered at a dose based on the lesion's location and the response to previous phototherapy sessions. Phototherapy is performed twice a week for 12 weeks.",[19],"Drug: 0.1% mometasone furoate cream",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","0.005% latanoprost gel","\\- Apply 0.005% latanoprost gel to the predetermined skin lesions twice daily (morning and evening) every day for 12 weeks. - Phototherapy is administered at a dose based on the lesion's location and the response to previous phototherapy sessions. Phototherapy is performed twice a week for 12 weeks.",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"0.1% mometasone furoate cream","\\- Apply 0.1% mometasone furoate cream to the predetermined skin lesions twice daily (morning and evening) for 12 weeks. - Phototherapy is administered at a dose based on the lesion's location and the response to previous phototherapy sessions. Phototherapy is performed twice a week for 12 weeks.",[15],[32],{"name":33,"affiliation":34,"role":35},"Reiva F Dwiyana, MD, PhD","Hasan Sadikin General Hospital","PRINCIPAL_INVESTIGATOR",[37],{"name":38,"role":39,"phone":40,"phoneExt":26,"email":41},"Safira M Pranata, MD","CONTACT","+6281220648003","safira14001@mail.unpad.ac.id",[43],{"facility":34,"status":26,"city":44,"state":45,"zip":46,"country":47,"countryCode":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":26},"Bandung","West Java","40161","Indonesia","ID",{"type":50,"coordinates":51},"Point",[52,53],107.60694,-6.92222,{"lat":53,"lon":52},{"type":56,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR","100594182","phase-2-0005-latanoprost-gel-for-nonsegmental-vitiligo-100594182",false,"NCT07016113","0.005% Latanoprost Gel for Nonsegmental Vitiligo","Comparison of the Effectiveness Between a Combination of 0.005% Latanoprost Gel With 308 nm Excimer Phototherapy and a Combination of 0.1% Mometasone Furoate Cream With 308 nm Excimer Phototherapy on Repigmentation of Nonsegmental Vitiligo in Children","Inclusion Criteria:\n\n* Patients with non-segmental vitiligo.\n* Patients with stable vitiligo for at least 6 months based on the Vitiligo Disease Activity (VIDA) score.\n* Aged 10-17 years.\n* Affected area \\\u003C10%.\n* Having at least two lesions to be treated. The vitiligo lesions selected for treatment must meet the following criteria:\n\n  1. Relatively the same size, ranging from a minimum of 1 cm² to 4 cm².\n  2. Bilateral location on both sides of the body.\n  3. A minimum distance of 5 cm between the studied lesions and other vitiligo lesions.\n  4. Not located on the palms, soles, or genital area.\n\nExclusion Criteria:\n\n* Use of topical therapy (corticosteroids, calcineurin inhibitors, psoralen, and antioxidants) for at least 2 weeks before the study, systemic therapy (corticosteroids, antioxidants, and vitamin D) for at least 4 weeks before the study, and phototherapy for at least 4 weeks before the study.\n* Presence of other active autoimmune diseases such as type 1 diabetes mellitus, thyroid disease, alopecia areata, rheumatoid arthritis, or Addison's disease, based on medical history and physical examination.\n* History of or current skin cancer, photosensitivity, or undergoing radiotherapy.\n* Allergy or contraindication to topical corticosteroids or latanoprost.\n* History of hypertension, asthma, diabetes mellitus, anemia, kidney, liver, neurological, or cardiovascular diseases.","ALL","10 Years","17 Years",{"count":68,"type":69},10,"ESTIMATED","INTERVENTIONAL",[72],"PHASE2","Latanoprost, a prostaglandin F2α (PGF2α) analog used for glaucoma treatment, is known to cause iris darkening, hypertrichosis, and periocular skin hyperpigmentation. PGF2α has been shown to stimulate the growth of melanocyte dendrites, increasing dendricity even at low doses, as well as enhancing tyrosinase activity and quantity, thereby promoting repigmentation. Studies on the use of 0.005% latanoprost gel in both children and adults with vitiligo have demonstrated effective repigmentation without reported side effects.",[75],"Vitiligo - Macular Depigmentation",[77,78],"Latanoprost","Vitiligo","NOT_YET_RECRUITING","2025-06-03",{"date":82,"type":83},"2025-06-11","ACTUAL",{"date":85,"type":69},"2025-07-01",{"date":87,"type":69},"2025-11-30",{"name":5,"class":6},1]